Please assess the completion status of the following clinical trial:

Trial Title: Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-986120 in Healthy Subjects and the Effects of Co-Administration of Midazolam and BMS-986120

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~1. Healthy male and female subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations~2. Body Mass Index (BMI) of 18 to 32 kg/m2, inclusive. BMI=Weight (kg)/\[Height(m)\]2~3. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) and men, ages 18 to 75, inclusive~Exclusion Criteria:~1. Concurrent, or use within 2-weeks of study drug administration, of marketed or investigational, non-steroidal anti-inflammatory compounds (NSAIDS), aspirin or other antiplatelet agents, oral or parenteral anticoagulants~2. Subjects at screening or prior to first dose with the following abnormal laboratory values upon repeat testing are excluded:~   * i) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>upper limit of normal (ULN)~  * ii) Total bilirubin \>ULN, thyroid-stimulating hormone (TSH) \>1.5 x ULN with T4 within normal limits (Subjects with mild unconjugated hyperbilirubinemia due to Gilbert's syndrome are excluded)~  * iii) CK \>3 x ULN (unless exercise related and CK-MB within normal limits)~  * iv) Activated partial thromboplastin (aPTT) or Prothrombin Time (PT)/International Normalized Ratio (INR) \>ULN~  * v) Blood urea nitrogen (BUN) or creatinine (Cr) \>ULN~3. Hemoglobin or hematocrit or platelet count \<lower limit of normal (LLN)~4. Bleeding time exceeding 8 minutes at pre-dose on Day -1~5. Subjects with micro- or macro-hematuria and/or fecal occult blood detected during screening, baseline or documented during other recent medical assessment, unless deemed not clinically significant by the Investigator and Medical Monitor~6. Any significant acute or chronic medical illness~7. Current or recent (within 3 months of study drug administration) gastrointestinal disease~8. Any major surgery within 12 weeks of study drug administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Panel 1: BMS-986120 or Placebo (Type: EXPERIMENTAL): BMS-986120 or Placebo multiple dose by mouth as specified
- Panel 2: BMS-986120 or Placebo (Type: EXPERIMENTAL): BMS-986120 or Placebo multiple dose by mouth as specified
- Panel 3: BMS-986120 or Placebo + Midazolam (Type: EXPERIMENTAL): BMS-986120 or Placebo (multiple dose) + Midazolam (single dose) by mouth as specified
- Panel 4: BMS-986120 or Placebo (Type: EXPERIMENTAL): BMS-986120 or Placebo multiple dose by mouth as specified

Based on this trial design, predict the completion outcome and termination type (if applicable).